Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer

<div>The diagnostic accuracy of serum miR-629 for NSCLC. (a) The diagnostic performance of serum miR-629 for discriminating NSCLC patients from healthy controls. (b) The diagnostic performance of CYFRA 21-1 for discriminating NSCLC patients from healthy controls. (c) The diagnostic performance of CEA for discriminating NSCLC patients from healthy controls.</div>

Disease Markers

fig2

Figure 2

Figure 2: Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer 